β-芬太尼诺辛对阿片类药物诱导的大鼠胃生长抑素分泌抑制的阻断作用。

Beta-funaltrexamine blockade of opioid-induced inhibition of somatostatin secretion from rat stomach.

作者信息

McIntosh C, Yago V, Kwok Y N

机构信息

Department of Physiology, University of British Columbia, Vancouver, Canada.

出版信息

Eur J Pharmacol. 1994 Jul 11;259(3):331-4. doi: 10.1016/0014-2999(94)90663-7.

DOI:10.1016/0014-2999(94)90663-7

PMID:7982463

Abstract

Opioid peptides are potent inhibitors of gastric somatostatin secretion. In the current investigation the effect of mu-opioid receptor blockade on responses to [D-Ala2,N-Me-Phe4,Gly5-ol]enkephalin (DAGO) was studied. Gastric inhibitory polypeptide (GIP; 1 nM) -stimulated secretion of immunoreactive somatostatin was almost completely inhibited by DAGO (1 microM). The mu-receptor antagonists, beta-funaltrexamine and naloxonazine, blocked the effect of DAGO. Pretreatment of rats with beta-funaltrexamine, 24 h prior to perfusion, reduced the percentage inhibition by DAGO from 88.6 +/- 5.2% to 50.7 +/- 9.3%. These studies support the involvement of mu-opioid inhibitory receptors in the regulation of gastric somatostatin secretion.

摘要

阿片肽是胃生长抑素分泌的强效抑制剂。在当前的研究中，研究了μ-阿片受体阻断对[D-丙氨酸2，N-甲基苯丙氨酸4，甘氨酸5-醇]脑啡肽（DAGO）反应的影响。胃抑制性多肽（GIP；1 nM）刺激的免疫反应性生长抑素分泌几乎被DAGO（1 μM）完全抑制。μ-受体拮抗剂β-芬太尼酰基酪氨酸和纳洛嗪阻断了DAGO的作用。在灌注前24小时用β-芬太尼酰基酪氨酸预处理大鼠，可使DAGO的抑制百分比从88.6±5.2%降至50.7±9.3%。这些研究支持μ-阿片抑制性受体参与胃生长抑素分泌的调节。